Denosumab delays metastases in castrate-resistant prostate cancer
Added: Wednesday 2 November 2011
The monoclonal antibody Denosumab has been shown in a recent analysis to delay bone metastases in patients with castrate-resistant prostate cancer. Unfortunately, the results did not amount to an overall survival advantage, though there are tangible quality-of-life benefits.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: